Spots Global Cancer Trial Database for PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies
Official Title: PD-1 Antibody Expressing Chimeric Antigen Receptor T Cells for Mesothelin Positive Advanced Malignancies
Study ID: NCT03030001
Study Description
Brief Summary: This is a single-arm, open-label, one center, dose escalation clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibody and chimeric antigen receptor targeting mesothelin in adult patients with mesothelin positive, recurrent or refractory malignant tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
Contact Details
Name: Qijun Qian, PhD
Affiliation: Shanghai Cell Therapy Engineering Research Institute
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
